Atorvastatin - Pfizer
Alternative Names: Atorvastatin calcium; Cardyl; CI 981; Lipitor; Prevencor; Sortis; Tahor; Xarator 10; YM 548; ZaratorLatest Information Update: 05 Nov 2023
At a glance
- Originator Parke-Davis
- Developer Astellas Pharma; Laboratorios Phoenix; Pfizer; University of Rochester
- Class Amides; Antihyperlipidaemics; Esters; Fatty acids; Fluorobenzenes; Heptanoic acids; Pyrroles; Small molecules
- Mechanism of Action HMG-CoA reductase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Cardiovascular disorders; Heart failure; Hypercholesterolaemia; Hyperlipoproteinaemia type IIa; Hyperlipoproteinaemia type III; Hypertriglyceridaemia; Low HDL cholesterol
- No development reported Metabolic syndrome
- Discontinued Alzheimer's disease; Neurological disorders; Veno-occlusive disorders
Most Recent Events
- 08 Apr 2021 Viatris terminates its marketing agreement with Astellas for Atorvastatin in Japan
- 06 Jan 2020 No recent reports on development identified - Phase-I/II for Metabolic syndrome in USA (PO)
- 06 Jan 2020 No recent reports on development identified - Phase-III for Veno-occlusive disorders (Prevention) in USA, Canada (PO, Capsule)